Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.

doi:10.1159/000443906

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.

Oncology research and treatment - 1 Jan 2016

Tausch Eugen, Mertens Daniel, Stilgenbauer Stephan

Abstract excerpt

Genomic markers are among the strongest prognostic factors in chronic lymphocytic leukemia (CLL). Chromosomal aberrations, IGHV and TP53 mutation status are well-established and essential to discriminate between a more indolent course of disease and a high-risk CLL, which requires an alternative treatment regimen. In addition, a variety of gene mutations with unclear prognostic value have been identified: SF3B1,...

Topics

Biomarkers, Tumor
Evidence-Based Medicine
Genetic Markers
Genetic Predisposition to Disease
Genetic Testing
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasm Proteins
Prognosis
Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 26890126
DOI: 10.1159/000443906

Genes

ATM
NOTCH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics